BELVIQ (ARNA)
BELVIQ continues to lead the market with 37.2% and 40.8% of the TRx, according to IMS and SH, respectively. BELVIQ TRx were up this week, 0.4% and 3.0% w/w, to 14,834 and 18,063 TRx, according to IMS and SH.
IMS:
NRx: down 0.2% (10,354 vs. 10,371; now 36.1% of the 4-drug total vs. 36.4% last week)
TRx: up 0.4% (14,834 vs. 14,769; now 37.2% of the 4-drug total vs. 37.5% last week)
Symphony Health:
NRx: up 2.6% (13,166 vs. 12,838; now 39.7% of the 4-drug total vs. 40.0% last week)
TRx: up 3.0% (18,063 vs. 17,544; now 40.8% of the 4-drug total vs. 41.1% last week)
Contrave (OREX)
Contrave TRx were up 1.7% and 4.2% w/w according to IMS and SH, respectively (13,154, up 1.7% (IMS), 15,766, up 4.2% (SH)) and the drug now has a ~33-36% market share. Contrave is in 2nd place in both datasets, having overtaken Qsymia in both IMS and SH TRx and closing in on Belviq.
IMS:
NRx: down 0.3% (9,925 vs. 9,950; now 34.6% of the 4-drug total vs. 35.0% last week)
TRx: up 1.7% (13,154 vs. 12,936; now 33.0% of the 4-drug total vs. 32.9% last week)
Symphony Health:
NRx: up 2.5% (12,264 vs. 11,960; now 37.0% of the 4-drug total vs. 37.3% last week)
TRx: up 4.2% (15,766 vs. 15,136; now 35.6% of the 4-drug total vs. 35.5% last week)
Qsymia (VVUS)
Qsymia TRx were up 0.5% and 2.2% according to IMS and SH, respectively, with its market share at 23%-29.3%. Qsymia scripts have remained flat over the last 20+ weeks of script data.
IMS:
NRx: up 0.7% (8,168 vs. 8,113; now 28.5% of the 4-drug total vs. 28.5% last week)
TRx: up 0.5% (11,675 vs. 11,612; now 29.3% of the 4-drug total vs. 29.5% last week)
Symphony Health:
NRx: up 2.3% (7,426 vs. 7,258; now 22.4% of the 4-drug total vs. 22.6% last week)
TRx: up 2.2% (10,183 vs. 9,968; now 23.0% of the 4-drug total vs. 23.4% last week)
Sigue muy estancada...Pensé que de cara al verano las ventas crecerían. Pero otra vez me he equivocado...
ARNA
